Old Web
English
Sign In
Acemap
>
Paper
>
PMU43 Biosimilar in China: Will Indication-Based Approach Help Improve Patient Access?
PMU43 Biosimilar in China: Will Indication-Based Approach Help Improve Patient Access?
2020
L.H. Cheung
A. Chaupin
S Duttagupta
Keywords:
China
Business
Biosimilar
Risk analysis (engineering)
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]